GNOM
Genomics & Biotechnology ETF
Reasons to Consider GNOM
High Growth Potential
Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1
Structural Tailwinds
Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 39% compound annual growth rate from 2024-2030.2
Targeted Exposure
GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, n.d., Technology Overviews of: Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy, and Genome Editing, all accessed 1 Nov 2024
| Key Information |
ETF Summary
The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
ETF Objective
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
| Trading Details |
| Distributions |
| Taxes |
ETF Prices
| NAV | Daily Change | |||
| Market Price | Daily Change |
Performance History
| Fund NAV | Market Price | Index | |
|---|---|---|---|
| Options Details |
Top Holdings
| Net Assets (%) | Ticker | Name | SEDOL | Shares Held | Market Value |
|---|---|---|---|---|---|
| Exposure |
| ETF Characteristics |
| ETF Risk Stats |